The Effect of Zoledronic Acid on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy

Israeli, Ron; Rosenberg, Steven; Saltzstein, Daniel R.; Gottesman, James E.; Goldstein, Howard R.; Hull, Gerald W.; Tran, Diep N. H.; Warsi, Ghulam; Lacerna, L.

doi:10.3816/cgc.2007.n.003

Cited by 105 publications

(70 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These men also showed a significant increase in both N-telopeptide (42%) and bone-specific alkaline phosphatase (16%) [59]. In 40 men with nonmetastatic prostate cancer receiving a gonadotropin-releasing hormone agonist, Michaelson et al [60] reported a significant loss in BMD Abbreviations: ADT, androgen deprivation therapy; BMD, bone mineral density; GnRH, gonadotropin-releasing hormone; LHRH, luteinizing hormone releasing hormone; PC, prostate cancer.…”

Section: Clinical Trial Evidencementioning

confidence: 99%

“…A methodological problem affecting many of these trials (e.g., [57,59,64]) is that it is unclear how much elemental calcium (the biologically active fraction of calcium) was provided or consumed. The concentration of elemental calcium varies in different forms of calcium supplements; for example, it is 40% in calcium carbonate but only 21% in calcium citrate [104].…”

Section: Discussionmentioning

confidence: 99%

“…Israeli et al [59] enrolled 222 men with nonmetastatic prostate cancer within 1 year of starting ADT to evaluate the effects of zoledronic acid with 500 mg calcium and a multivitamin containing 400 -500 IU vitamin D versus placebo with 500 mg calcium and a multivitamin containing 400 -500 IU vitamin D. They reported a 2% decrease in lumbar spine BMD and 2.1% decrease in total hip BMD in patients in the placebo plus Ca-D group. These men also showed a significant increase in both N-telopeptide (42%) and bone-specific alkaline phosphatase (16%) [59].…”

Section: Clinical Trial Evidencementioning

confidence: 99%

See 2 more Smart Citations

Calcium and Vitamin D Supplementation During Androgen Deprivation Therapy for Prostate Cancer: A Critical Review

Datta

Schwartz

2012

The Oncologist

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Describe the prevalence of bone loss with androgen deprivation therapy for prostate cancer.2. Discuss the possible increased risk of cardiovascular disease and of advanced prostate cancer with high calcium intake.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTBackground. Loss of bone mineral density is an unintended consequence of androgen deprivation therapy in men with prostate cancer. Supplementation with calcium and/or vitamin D in these men seems logical and is advocated by many lay and professional groups. Methods. We reviewed guidelines for calcium and vitamin D supplementation and the results of clinical trials of calcium and vitamin D supplementation on bone mineral density in men with prostate cancer undergoing androgen deprivation therapy.Results. Whether supplementation of men undergoing androgen deprivation therapy with calcium and/or vitamin D results in higher bone mineral density than no supplementation has not been tested. The results of 12 clinical

show abstract

Section: Clinical Trial Evidencementioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Clinical Trial Evidencementioning

confidence: 99%

See 1 more Smart Citation

Calcium and Vitamin D Supplementation During Androgen Deprivation Therapy for Prostate Cancer: A Critical Review

Datta

Schwartz

2012

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Numerous randomized controlled trials have explored the effects of BPs on BMD in the setting of ADT for nonmetastatic prostate Bone health in prostate cancer cancer (Table 2), [21][22][23][24][25][26][27][28][29][30][31][32][33][34] but to date none have had sufficient power to demonstrate a reduction in fractures. These trials demonstrate clearly that BPs are effective in reducing BMD loss associated with ADT for at least 1 year.…”

Section: Bisphosphonatesmentioning

confidence: 99%

Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options

Egerdie

Saad

2013

CUAJ

View full text Add to dashboard Cite

Osteoporosis and bone fractures are frequently overlooked complications of androgen deprivation therapy in men with nonmetastatic prostate cancer. All such patients should have their bone mineral density (BMD) monitored and be offered preventive measures, such as calcium and vitamin D supplementation; patients with low BMD should be offered treatment. Several agents, including bisphosphonates, are available (although this use is currently offlabel), and upcoming treatments, such as denosumab and toremifene, have shown promise in reducing fracture risk in these patients. RésuméL'ostéoporose et les fractures osseuses sont des complications souvent négligées du traitement antiandrogénique chez les hommes atteints d'un cancer de la prostate non métastatique. La teneur minérale des os de ces patients devrait être surveillée, et des mesures préventives, comme la prise de suppléments de calcium et de vitamine D, devraient être offertes. Les patients présentant une faible teneur minérale des os devraient se voir offrir un traitement approprié. Plusieurs agents, y compris des bisphosphonates, sont offerts sur le marché (quoique cette indication ne soit pas officiellement approuvée à l'heure actuelle), et des traitements en cours d'étude, comme le dénosumab et le torémifène, se sont révélés prometteurs dans la réduction du risque de fracture chez ces patients.

show abstract

“…1 Bone mineral density (BMD) is reduced by 0.6-5.3% annually in patients with locally advanced disease and 2.3-6.6% in patients with metastatic disease receiving ADT, exceeding by 5-to 10-fold the normal bone loss rates of similarly aged otherwise healthy men and prostate cancer patients not receiving ADT. [2][3][4][5][6][7][8] Consequently, patients receiving ADT are 7-45% more likely to experience a fracture than patients not receiving ADT. [9][10][11] Bisphosphonates have been shown to prevent bone loss and related complications in patients with locally advanced and metastatic prostate cancer and should be considered as part of cancer treatment when ADT is initiated in these patients.…”

Section: Introductionmentioning

confidence: 99%

Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates

Polascik

2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Androgen-deprivation therapy, a mainstay in the treatment of locally advanced and metastatic prostate cancer, is associated with significant bone loss and related complications, such as fracture. Bisphosphonates, osteoclast inhibitors, are effective in preventing skeletal-related events in patients with metastatic prostate cancer and also in preventing bone loss in patients with locally advanced disease. Understanding the management of bone health, including identifying patients at risk, the most appropriate therapy, and monitoring and managing side effects, is critical. This review provides the most recent bone health risk factor and bisphosphonate data available for prostate cancer patients.

show abstract

The Effect of Zoledronic Acid on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy

Cited by 105 publications

References 29 publications

Calcium and Vitamin D Supplementation During Androgen Deprivation Therapy for Prostate Cancer: A Critical Review

Calcium and Vitamin D Supplementation During Androgen Deprivation Therapy for Prostate Cancer: A Critical Review

Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options

Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates

Contact Info

Product

Resources

About